These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 25772046)

  • 1. Commentary on "pANCA positivity predicts lower clinical response to infliximab therapy among patients with IBD".
    Leung E
    South Med J; 2015 Mar; 108(3):144. PubMed ID: 25772046
    [No Abstract]   [Full Text] [Related]  

  • 2. pANCA positivity predicts lower clinical response to infliximab therapy among patients with IBD.
    Nguyen DL; Nguyen ET; Bechtold ML
    South Med J; 2015 Mar; 108(3):139-43. PubMed ID: 25772045
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Efficacy of infliximab in treatment on inflammatory bowel disease and factors affecting the therapeutic effect].
    Zhou Y; Chen Y
    Nan Fang Yi Ke Da Xue Xue Bao; 2013 Dec; 33(12):1833-8. PubMed ID: 24369257
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serological markers in diagnosis of pediatric inflammatory bowel disease and as predictors for early tumor necrosis factor blocker therapy.
    Olbjørn C; Cvancarova Småstuen M; Thiis-Evensen E; Nakstad B; Vatn MH; Perminow G
    Scand J Gastroenterol; 2017 Apr; 52(4):414-419. PubMed ID: 27887202
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical use and mechanisms of infliximab treatment on inflammatory bowel disease: a recent update.
    Guo Y; Lu N; Bai A
    Biomed Res Int; 2013; 2013():581631. PubMed ID: 23484133
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Letter: infliximab therapy in inflammatory bowel disease patients after liver transplantation.
    Indriolo A; Fagiuoli S; Pasulo L; Fiorino G; Danese S; Ravelli P
    Aliment Pharmacol Ther; 2013 Apr; 37(8):840-2. PubMed ID: 23496317
    [No Abstract]   [Full Text] [Related]  

  • 7. Perinuclear antineutrophilic cytoplasmic antibody and response to treatment in diarrheic dogs with food responsive disease or inflammatory bowel disease.
    Luckschander N; Allenspach K; Hall J; Seibold F; Gröne A; Doherr MG; Gaschen F
    J Vet Intern Med; 2006; 20(2):221-7. PubMed ID: 16594575
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Treatment of inflammatory bowel disease with infliximab: experience in 25 patients].
    Simian D; Quijada MI; Lubascher J; Acuña R; Quera R
    Rev Med Chil; 2013 Sep; 141(9):1158-65. PubMed ID: 24522419
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preoperative infliximab therapy does not increase morbidity and mortality after laparoscopic resection for inflammatory bowel disease.
    Krane MK; Allaix ME; Zoccali M; Umanskiy K; Rubin MA; Villa A; Hurst RD; Fichera A
    Dis Colon Rectum; 2013 Apr; 56(4):449-57. PubMed ID: 23478612
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Infliximab reduces hospitalizations and surgery interventions in patients with inflammatory bowel disease: a systematic review and meta-analysis.
    Costa J; Magro F; Caldeira D; Alarcão J; Sousa R; Vaz-Carneiro A
    Inflamm Bowel Dis; 2013 Sep; 19(10):2098-110. PubMed ID: 23860567
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Infliximab therapy for patients with inflammatory bowel disease: 10 years on.
    Van Assche G; Vermeire S; Rutgeerts P
    Eur J Pharmacol; 2009 Nov; 623 Suppl 1():S17-25. PubMed ID: 19837056
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety of infliximab in children with IBD: the experience of an academic center in WV.
    Northcutt M; Al-Subu A; Bella B; Elitsur Y
    W V Med J; 2014; 110(3):26-9. PubMed ID: 24984403
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Current status of new drug development for inflammatory bowel diseases].
    Kohgo Y; Tanabe H; Fujiya M
    Nihon Rinsho; 2012 Feb; 70 Suppl 1():378-82. PubMed ID: 23126121
    [No Abstract]   [Full Text] [Related]  

  • 14. [New inflammatory bowel disease drugs targeting the inflammatory cascade].
    Desreumaux P
    Gastroenterol Clin Biol; 2001 Apr; 25(4 Suppl):B72-8. PubMed ID: 11449147
    [No Abstract]   [Full Text] [Related]  

  • 15. Trough s-infliximab and antibodies towards infliximab in a cohort of 79 IBD patients with maintenance infliximab treatment.
    Marits P; Landucci L; Sundin U; Davidsdottir L; Nilsson J; Befrits R; Wikström AC; Eberhardson M
    J Crohns Colitis; 2014 Aug; 8(8):881-9. PubMed ID: 24486178
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The immunogenic part of infliximab is the F(ab')2, but measuring antibodies to the intact infliximab molecule is more clinically useful.
    Ben-Horin S; Yavzori M; Katz L; Kopylov U; Picard O; Fudim E; Coscas D; Bar-Meir S; Goldstein I; Chowers Y
    Gut; 2011 Jan; 60(1):41-8. PubMed ID: 20519742
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnostic value of anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease.
    Peeters M; Joossens S; Vermeire S; Vlietinck R; Bossuyt X; Rutgeerts P
    Am J Gastroenterol; 2001 Mar; 96(3):730-4. PubMed ID: 11280542
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IBD: Infliximab dose optimization in IBD-proactive or reactive?
    Armuzzi A; Felice C
    Nat Rev Gastroenterol Hepatol; 2014 Dec; 11(12):706-8. PubMed ID: 25331632
    [No Abstract]   [Full Text] [Related]  

  • 19. The MMAS-8, a screening tool for determining nonadherent behavior, should not be dismissed in IBD.
    Trindade AJ; Tinsley A; Kornbluth A; Ullman TA
    Am J Gastroenterol; 2012 Jun; 107(6):951-2; author reply 952. PubMed ID: 22664851
    [No Abstract]   [Full Text] [Related]  

  • 20. Serological markers of inflammatory bowel disease in children from the Western region of Saudi Arabia.
    Saadah OI; Al-Mughales JA
    Arab J Gastroenterol; 2013 Jun; 14(2):78-82. PubMed ID: 23820506
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.